According to Zhitong Finance App, Guangji Pharmaceutical (000952.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 312 million yuan, an increase of 9.71% over the previous year; achieved a net loss of 579.451 million yuan attributable to shareholders of listed companies; realized a net loss of 65.5887 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss; and basic earnings per share - 0.1671 yuan.

In the first half of 2026, the company's marketing system revolved around the company's overall strategic deployment, guided by market terminal demand, continuously optimized the three-dimensional marketing system and omni-channel layout, strengthened the core capabilities of brand building and refined terminal operation, and achieved a steady and steady improvement in the overall business situation; the company continued to optimize refined internal operation management and steadily promoted work related to cost reduction and efficiency, and achieved a significant decrease in expenses during the current period compared to the same period last year; at the same time, the revenue disposal of the company's idle assets increased year-on-year. Due to the combined effects of various active management initiatives and changes in earnings, the company's net profit attributable to shareholders of listed companies decreased losses compared to the same period last year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.